Skip to content
Search

Latest Stories

London pharmacist jailed for supplying Norwich drug addict with 'under the counter drugs'

A community pharmacist who supplied a drug addict with "under the counter drugs" has been jailed for 18 months.

Dushyant Patel, 67, a London pharmacist with more than 40 years' experience, had supplied class C drugs to a drug user in Norwich for months in 2020.


Police identified Patel as a suspect four months after the death of drug user, Alisha Siddiqi, whose body was found at a property in Colossus Way, Costessey, in August 2020.

An initial post-mortem examination was inconclusive, but toxicology results later showed she died from an overdose of prescription medication.

An analysis of her phone revealed that she had frequent communication with Patel between January and August 2020.

Class C drugs sold without prescription

There was also communication regarding transactions relating to the sale of prescription drugs including class C drugs, without a prescription, namely Zolpidem and Zopiclone.

Patel was identified as a suspect and later charged with drugs offences.

He was jailed at Norwich Crown Court in December after a trial in August when he was found guilty of two counts of being concerned in supplying a controlled drug between March and August 2020.

The court heard Patel had not been charged with any offences in relation to Siddiqi's death.

Sentencing Patel to 18 months in custody judge Alice Robinson said it had been a "very serious breach of trust" by the defendant who had been a pharmacist for over 40 years.

Patel was told messages on his phone showed he had been supplying her with these drugs.

Judge Robinson said must have known the victim was "misusing" these drugs or was "addicted to them and was therefore vulnerable".

The court heard Patel and his wife ran a pharmacy in East London which was the "backdrop" to this offending.

He had supplied drugs "under the counter" to Siddiqi over the course of a few months.

The prosecution said he was receiving money in exchange.

Peter Pride, for Patel, said it was "bewildering" that he acted in this way for "quite modest sums of money".

Patel, who he insisted was "a man of means", had "tarnished his reputation" by getting involved in this drugs supply.

He said he has had a career "spanning decades in which a very valuable service" was provided to customers of the pharmacy, most notably during the coronavirus pandemic.

The court was also told Patel was a full-time carer for his 90-year-old mother.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less